Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2008
Event: Notice of failure to satisfy Nasdaq continued listing rules regarding board independence and audit committee composition.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
- Board Composition Change: David N. Gill resigned as a director effective July 24, 2008.
- Regulatory Non-Compliance: The resignation caused the Company to fall out of compliance with Nasdaq Marketplace Rule 4350(c)(1) (majority independent directors) and Rule 4350(d)(2)(A) (audit committee of at least three independent members).
- Listing Status: The Company received a Staff Deficiency Letter from Nasdaq on August 6, 2008, notifying it of the deficiency.
Outlook, Risks, and Management Commentary
- Cure Period: Nasdaq has granted a cure period to regain compliance. The deadline is the earlier of the next annual shareholders' meeting or July 24, 2009. If the next annual meeting is held before January 20, 2009, the deadline is January 20, 2009.
- Management Action: The Company has begun identifying a qualified replacement to fill the vacancies left by Mr. Gill.
- Risk of Delisting: If the Company fails to regain compliance within the cure period, its common stock is subject to delisting upon notification by Nasdaq staff. This determination may be appealed.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new independent director to restore board majority independence.
- Confirm the date of the next annual shareholders' meeting to determine the exact expiration of the cure period.
- Monitor subsequent filings for evidence of compliance submitted to Nasdaq.
- Review the press release (Exhibit 99.1) for additional details on the resignation and replacement search.